Crescent Biopharma Inc

Research Crescent Biopharma Inc (CBIO) on Bullrun: market cap USD 496.35M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCBIO
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 496.35M
• Financial periodFY2025
• RevenueUSD 10.84M
• Net incomeUSD 153.94K
• Free cash flow-USD 72.45M

Valuation Snapshot

latest market cap is USD 496.35M.

About Crescent Biopharma Inc

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc.

Frequently asked questions

What is Crescent Biopharma Inc's market cap?

Crescent Biopharma Inc's market capitalization is USD 496.35M.

What does Crescent Biopharma Inc do?

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.